NASDAQ · CGCHealthcarePharmaceuticals

Canopy Growth financials

$0.9251−0.03%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Mar 31
FY25
Mar 31
FY24
Mar 31
FY23
Mar 31
FY22
Mar 31
FY21
Mar 31
FY20
Mar 31
FY19
Mar 31
Revenue$249.5M$218.2M$254.3M$246.4M$430.1M$607.2M$398.8M$226.3M
Gross profit$94.9M$86.5M$94.4M-$47.0M-$100.4M$127.5M-$31.7M$28.2M
Gross margin38.0%39.6%37.1%−19.1%−23.3%21.0%−7.9%12.5%
Operating income-$68.0M-$59.7M-$120.3M-$1.94B-$519.6M-$1.24B-$1.67B-$637.5M
Net income-$189.1M-$353.6M-$513.0M-$2.42B-$248.0M-$1.74B-$1.32B-$736.3M
Net margin−75.8%−162.1%−201.7%−983.7%−57.7%−287.4%−331.3%−325.3%
Diluted EPS$-0.63$-3.29$-6.86$-52.26$-6.34$-46.90$-38.00$-27.60
EBITDA-$41.8M-$29.7M-$81.0M-$259.7M-$430.9M-$581.9M-$920.7M-$590.5M
Operating cash flow-$45.9M-$115.2M-$208.5M-$412.2M-$436.7M-$465.7M-$772.6M-$535.0M
Free cash flow-$49.7M-$122.7M-$211.1M-$418.9M-$466.0M-$630.2M-$1.61B-$1.27B
Diluted shares298.0M107.6M74.8M46.4M39.1M37.2M34.8M26.7M

Balance sheet

Period endMar 31Mar 31Mar 31Mar 31Mar 31Mar 31
Cash & equivalents$262.3M$79.1M$125.9M$493.6M$776.0M$1.15B
Short-term investments$0.00$12.3M$24.5M$78.0M$595.7M$1.14B
Total debt$167.8M$211.3M$441.7M$966.2M$1.50B$1.58B
Total assets$804.7M$637.7M$961.6M$1.80B$5.61B$6.82B
Total liabilities$302.9M$305.1M$665.4M$1.24B$1.98B$3.20B
Shareholders' equity$501.8M$332.5M$296.2M$561.9M$3.59B$3.49B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology